Global pharma major Lupin announced that it has divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, a U.S. biopharmaceutical company focused exclusively on Women’s Health.
Lupin’s U.S. Commercial Women’s Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Under the terms of the agreement, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones.
Dr. Fabrice Egros, President – Global Corporate Development, Lupin, said, “We are very pleased to divest our U.S. Commercial Women’s Health Specialty business, including SOLOSEC®, to Evofem. This divestment is another step in aligning our U.S. specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases.”
Saundra Pelletier, Chief Executive Officer, Evofem, remarked “The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. SOLOSEC is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth potential”.
KYBORA, a global advisory firm and investment bank with direct operations in all key biopharma markets around the world, served as exclusive advisor to Lupin in the transaction.
Thomas F. Gillespie III, Vice President, Global Business Development of Lupin added “I hired KYBORA for a tough sell-side assignment. They leveraged their deep network of relationships to find buyers that my team and I were thinking of, but quite a few more that we did not. KYBORA’s close relationships with numerous companies, particularly smaller caps and private biotechs really sets them apart. And most importantly, they got us results. We ended up with a closed deal. Not just interesting leads.”
“This transaction demonstrates KYBORA’s industry expertise and global advisory leadership in M&A.We are delighted to have served as advisor to Lupin and look forward to additional collaborations with them in the future “, said Alan Vanderborght, CEO, KYBORA.
